Sublimity Therapeutics   Report issue

For profit Phase 2
Founded: Dublin Ireland (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2010
NCT01033305
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Sigmoid Pharma | Sublimity Therapeutics Holdco Limited | Sublimity Therapeutics (HoldCo) Ltd

Active Ingredients

Drugs in Phase 2 Trials (1)

cyclosporine (sandimmune) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1